RU2018133158A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018133158A3 RU2018133158A3 RU2018133158A RU2018133158A RU2018133158A3 RU 2018133158 A3 RU2018133158 A3 RU 2018133158A3 RU 2018133158 A RU2018133158 A RU 2018133158A RU 2018133158 A RU2018133158 A RU 2018133158A RU 2018133158 A3 RU2018133158 A3 RU 2018133158A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298113P | 2016-02-22 | 2016-02-22 | |
| US62/298,113 | 2016-02-22 | ||
| PCT/IB2017/050962 WO2017145040A1 (en) | 2016-02-22 | 2017-02-20 | Methods for using fxr agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018133158A RU2018133158A (ru) | 2020-03-24 |
| RU2018133158A3 true RU2018133158A3 (ru) | 2020-06-08 |
| RU2737324C2 RU2737324C2 (ru) | 2020-11-27 |
Family
ID=58192341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018133158A RU2737324C2 (ru) | 2016-02-22 | 2017-02-20 | Способы применения агонистов fxr |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11110083B2 (ru) |
| EP (2) | EP3842043A1 (ru) |
| JP (1) | JP6941109B2 (ru) |
| KR (1) | KR20180115700A (ru) |
| CN (1) | CN108697703A (ru) |
| AU (1) | AU2017223154B2 (ru) |
| CA (1) | CA3014733A1 (ru) |
| DK (1) | DK3419624T3 (ru) |
| ES (1) | ES2862194T3 (ru) |
| HU (1) | HUE053743T2 (ru) |
| IL (1) | IL261036A (ru) |
| PL (1) | PL3419624T3 (ru) |
| PT (1) | PT3419624T (ru) |
| RU (1) | RU2737324C2 (ru) |
| SI (1) | SI3419624T1 (ru) |
| TW (1) | TW201733583A (ru) |
| WO (1) | WO2017145040A1 (ru) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11229634B2 (en) | 2016-02-22 | 2022-01-25 | Novartis Ag | Methods for treating gastrointestinal disorders using FXR agonists |
| RU2743075C2 (ru) * | 2016-02-22 | 2021-02-15 | Новартис Аг | Способы применения агонистов fxr |
| JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
| AU2017339826A1 (en) * | 2016-10-05 | 2019-04-04 | Novartis Ag | Combination compositions comprising FXR agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| AR114930A1 (es) | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
| WO2019053582A1 (en) * | 2017-09-13 | 2019-03-21 | Novartis Ag | COMBINATIONS HAVING FXR AGONISTS |
| AU2018360575A1 (en) | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| KR102732404B1 (ko) | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 화합물 |
| JP7264905B2 (ja) | 2017-11-01 | 2023-04-25 | ブリストル-マイヤーズ スクイブ カンパニー | ファルネソイドx受容体モジュレーターとしての多環化合物 |
| KR102731924B1 (ko) | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
| SG11202003827YA (en) | 2017-11-01 | 2020-05-28 | Bristol Myers Squibb Co | Bridged bicyclic compounds as farnesoid x receptor modulators |
| CA3081656A1 (en) * | 2017-11-30 | 2019-06-06 | Novartis Ag | Fxr agonists for the treatment of liver diseases |
| US11667629B2 (en) | 2017-12-22 | 2023-06-06 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
| EP3852735A4 (en) * | 2018-09-18 | 2022-06-08 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES |
| EP3924329A2 (en) | 2019-02-15 | 2021-12-22 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| US12319676B2 (en) | 2019-02-15 | 2025-06-03 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid X receptor modulators |
| JP7465883B2 (ja) | 2019-02-15 | 2024-04-11 | ブリストル-マイヤーズ スクイブ カンパニー | ファルネソイドx受容体モジュレータとしての置換二環式化合物 |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| KR20220035366A (ko) * | 2019-07-18 | 2022-03-22 | 엔요 파마 | Eyp001을 사용하는 개선된 치료 |
| JP2022550312A (ja) * | 2019-09-30 | 2022-12-01 | ノバルティス アーゲー | Fxrアゴニストの使用を含む処置 |
| EP4090327B1 (en) | 2020-01-15 | 2025-03-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Hbv感染の処置のためのfxrアゴニストとifnの相乗効果 |
| CN114903905B (zh) * | 2021-02-09 | 2024-04-02 | 中国人民解放军陆军军医大学第二附属医院 | 甘氨脱氧胆酸在制备治疗肝内胆汁淤积药物中的应用及其药物组合物 |
| CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003290700A1 (en) * | 2002-11-22 | 2004-06-18 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| RU2743075C2 (ru) | 2016-02-22 | 2021-02-15 | Новартис Аг | Способы применения агонистов fxr |
| US11229634B2 (en) | 2016-02-22 | 2022-01-25 | Novartis Ag | Methods for treating gastrointestinal disorders using FXR agonists |
-
2017
- 2017-02-20 JP JP2018544147A patent/JP6941109B2/ja not_active Expired - Fee Related
- 2017-02-20 RU RU2018133158A patent/RU2737324C2/ru active
- 2017-02-20 PT PT177083417T patent/PT3419624T/pt unknown
- 2017-02-20 WO PCT/IB2017/050962 patent/WO2017145040A1/en not_active Ceased
- 2017-02-20 DK DK17708341.7T patent/DK3419624T3/da active
- 2017-02-20 CN CN201780012782.2A patent/CN108697703A/zh active Pending
- 2017-02-20 EP EP21150907.0A patent/EP3842043A1/en not_active Withdrawn
- 2017-02-20 AU AU2017223154A patent/AU2017223154B2/en not_active Ceased
- 2017-02-20 EP EP17708341.7A patent/EP3419624B1/en active Active
- 2017-02-20 HU HUE17708341A patent/HUE053743T2/hu unknown
- 2017-02-20 KR KR1020187023975A patent/KR20180115700A/ko not_active Withdrawn
- 2017-02-20 CA CA3014733A patent/CA3014733A1/en not_active Abandoned
- 2017-02-20 PL PL17708341T patent/PL3419624T3/pl unknown
- 2017-02-20 ES ES17708341T patent/ES2862194T3/es active Active
- 2017-02-20 SI SI201730697T patent/SI3419624T1/sl unknown
- 2017-02-20 US US16/078,431 patent/US11110083B2/en not_active Expired - Fee Related
- 2017-02-22 TW TW106105852A patent/TW201733583A/zh unknown
-
2018
- 2018-08-07 IL IL261036A patent/IL261036A/en unknown
-
2021
- 2021-07-23 US US17/383,634 patent/US20210386729A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017145040A1 (en) | 2017-08-31 |
| EP3419624B1 (en) | 2021-01-13 |
| EP3842043A1 (en) | 2021-06-30 |
| US20210386729A1 (en) | 2021-12-16 |
| CA3014733A1 (en) | 2017-08-31 |
| AU2017223154A1 (en) | 2018-08-30 |
| IL261036A (en) | 2018-10-31 |
| JP2019511476A (ja) | 2019-04-25 |
| JP6941109B2 (ja) | 2021-09-29 |
| AU2017223154B2 (en) | 2019-08-15 |
| PL3419624T3 (pl) | 2021-08-02 |
| ES2862194T3 (es) | 2021-10-07 |
| CN108697703A (zh) | 2018-10-23 |
| US11110083B2 (en) | 2021-09-07 |
| HUE053743T2 (hu) | 2021-07-28 |
| DK3419624T3 (da) | 2021-04-19 |
| EP3419624A1 (en) | 2019-01-02 |
| KR20180115700A (ko) | 2018-10-23 |
| TW201733583A (zh) | 2017-10-01 |
| RU2737324C2 (ru) | 2020-11-27 |
| RU2018133158A (ru) | 2020-03-24 |
| HK1257649A1 (en) | 2019-10-25 |
| US20190083481A1 (en) | 2019-03-21 |
| SI3419624T1 (sl) | 2021-05-31 |
| PT3419624T (pt) | 2021-04-07 |